Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.09
  • Today's Change0.02 / 0.65%
  • Shares traded7.99k
  • 1 Year change-33.97%
  • Beta-0.7803
Data delayed at least 15 minutes, as of Mar 28 2024 10:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

  • Revenue in EUR (TTM)9.45m
  • Net income in EUR-22.32m
  • Incorporated2017
  • Employees101.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MediGene AG-100.00bn-100.00bn52.07m87.00--1.73----------1.23-----------19.63---21.81--91.59---126.68----0.1035--187.9232.3116.56---8.43--
Apontis Pharma AG-100.00bn-100.00bn52.70m174.00------------------------------------------------8.87--460.79------
BRAIN Biotech AG55.23m-8.40m74.28m311.00--3.63--1.35-0.3843-0.38432.530.93750.7778----167,351.50-11.67-10.71-15.18-14.4656.1256.16-15.01-17.47---2.800.00--11.7914.12-25.63--14.47--
Haemato AG260.81m9.61m86.81m78.009.010.57898.060.33281.841.8450.1028.671.479.8012.483,343,690.005.412.016.452.707.568.423.681.211.66--0.0203157.20-12.95-3.0325.393.32-5.75-16.74
4Sc AG304.00k-8.24m87.99m15.00--17.42--289.45-0.8144-0.81440.03010.49950.0236--3.6820,266.67-63.84-39.49-77.78-42.8468.7592.24-2,709.54-337.74----0.00---30.28-40.7842.64---56.05--
Cantourage Group SE-100.00bn-100.00bn97.49m2.00--2.20----------3.72----------------------------0.00--------------
Heidelberg Pharma AG9.45m-22.32m143.08m101.00--2.78--15.13-0.4763-0.47630.2021.100.18160.39149.4092,686.18-42.86-51.65-82.16-73.5172.8347.30-236.05-216.542.57--0.1006--958.0457.6724.62--8.06--
Data as of Mar 28 2024. Currency figures normalised to Heidelberg Pharma AG's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.